Furthermore, the high levels of PB-associated eMDSCs, such as CD33+CD11b+ HLA-DR−/lowCD14−CD15− cells, in AML patients indicate a potential use as a diagnostic index [115]. This evidence concerns the gene CD33 and acute myeloid leukemia.